Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 581-588

  Alessandrino, E P ^b   Porta, Matteo G Della ^a,b   Malcovati, Luca ^a,b   Jackson, Christopher H ^c   Pascutto, Cristiana ^a,b   Bacigalupo, A ^d   Van Lint, Mt ^d   Falda, M ^e   Bernardi, M ^f   Onida, F ^w   Guidi, S ^v   Iori, Anna Paola ⁱ   Cerretti, R ^j   Marenco, P ^k   Pioltelli, P ^z   Angelucci, E ^m   Oneto, Rosi ^d   Ripamonti, Francesco ^a,b   Rambaldi, A ⁿ   Bosi, A ^v   Cazzola, Mario ^a,b   Levis, A ^o   Bandini, G ^p   Casini, M ^q   Rossi, G ^r   Baronciani, D ^m   La Nasa, G ^s   Milone, G ^t   Mordini, N ^u   Corradini, P ^g   Milani, R ^g   Morra, E ^k   Lambertenghi Deliliers, G ^w   Ciceri, F ^f   Castagna, L ^x   Narni, F ^y   Selleri, C ^aa   Scime R ^ab   Iannitto, E ^ac   Musso, M ^ad   Locatelli, F ^b   Zecca, M ^b   Martelli, F ^ae   Visani, G ^af   Di Bartolomeo, P ^ag   Cavanna, L ^ah   Papineschi, F ^ai   Messina, G ^aj   Merli, F ^ak   Ior, A P ⁱ   Foa R ⁱ   Locasciulli, A ^al   Majolino, I ^al   Chiusolo, P ^am   Leone, G ^am   Arcese, W ^j   Carella, A M ^an   Cascavilla, N ^an   Mazza, P ^ao   Bruno, B ^ap   Boccadoro, M ^ap   Fanin, R ^aq   Cerno, M ^aq   Raimondi, R ^ar   more..

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l SAN GERARDO HOSPITAL   (Italy)

^m Ospedale Oncologico A Businco   (Italy)

ⁿ OSPEDALI RIUNITI   (Italy)

^o Ospedale SS Antonio e Biagio Alessandria   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q Ospedale Regionale   (Italy)

^r SPEDALI CIVILI   (Italy)

^s UNIVERSITY OF CAGLIARI   (Italy)

^t Ospedale Ferrarotto Catania   (Italy)

^u S CROCE E CARLE HOSPITAL   (Italy)

^v UNIVERSITY OF FLORENCE   (Italy)

^w FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^x HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^y UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^z UNIVERSITY OF MILANO BICOCCA   (Italy)

^aa UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ab VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^ac UNIVERSITY OF PALERMO   (Italy)

^ad LA MADDALENA CANCER CENTER   (Italy)

^ae UNIVERSITY OF PERUGIA   (Italy)

^af SAN SALVATORE HOSPITAL   (Italy)

^ag Ospedale Civile   (Italy)

^ah GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^ai UNIVERSITY OF PISA   (Italy)

^aj Divisione di Ematologia   (Italy)

^ak S MARIA NUOVA HOSPITAL   (Italy)

^al SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^am CATHOLIC UNIVERSITY   (Italy)

^an CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^ao Ospedale Nord   (Italy)

^ap UNIVERSITY OF TURIN   (Italy)

^aq UNIVERSITY OF UDINE   (Italy)

^ar SAN BORTOLO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTE COUNT; WORLD HEALTH ORGANIZATION;

EID: 84879407728     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23458     Document Type: Article

References (34)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005;352:536–538.
2. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–7603.
3. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496–2506.
4. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64–69.
5. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384–1395.
6. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118:6239–6246.
7. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53–57.
8. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376–3382.
9. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:3578–3584.
10. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
11. Appelbaum FR. The role of hematopoietic cell transplantation as therapy for myelodysplasia. Best Pract Res Clin Haematol 2011;24:541–547.
12. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
13. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
14. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
15. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433–1440.
16. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008;112:895–902.
17. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010;28:405–411.
18. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012;119:5632–5639.
19. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–585.
20. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.
22. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010;95:476–484.
23. Kalbfleisch JD, Lawless JF, Vollmer WM. Estimation in Markov models from aggregate data. Biometrics 1983;39:907–919.
24. Kay R. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 1986;42:855–865.
25. Sung L, Buckstein R, Doyle JJ, et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: A decision analysis. Cancer 2003;97:592–600.
26. Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000;110:614–619.
27. Bush NE, Donaldson GW, Haberman MH, et al. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: A longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000;6:576–591.
28. Jackson CH. Multi-state models for panel data: The msm package for R. Journal of Statistical Software 2011;38:1–28.
29. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 1996;87:51–58.
30. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110:620–630.
31. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLAidentical siblings as treatment for myelodysplasia. Blood 2002;100:1997–2004.
32. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012;120:1398–1408.
33. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
34. Koreth J, Pidala J, Perez WS, et al. The role of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in older patients with denovo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol, in press.